BMT

1.61%

30.5¢ beamtree holdings limited

Ann: Q3 FY23 Trading Update Presentation, page-7

First 7 Last

Share
Profile

Follow
edgck

1,742 Posts.

115

03/05/23

08:05

Post #: 67576262
Share

Originally posted by Brett M H: ↑

Just spotted this little article about BMT.

Clearly it was a very solid update during the week - with great organic & other growth, and overheads increases significantly below revenue increases.

Would now like to see that they are constantly cash flow positive - and hopefully also getting close to a profit for the full year.

See article below:

Beamtree Holdings reports 51% revenue growth

While not a stock Morgans follows closely Wilkie said he thought Beamtree Holdings (ASX:BMT)announced a quite positive trading update for Q3 FY23 which saw its share price lift ~12% for the week.

BMT proprietary AI subscription based system called RippleDown offers decision support and data insights solutions to the healthcare industry and consists of two components including RippleDown Auditor and RippleDown Expert.

BMT reported continued revenue growth of +51% on pcp, strong organic revenue growth of 24%, and an operating profit improvement of 25% on pcp, which it put down to contract wins both in Australia and internationally.

BMT said the Abbott partnership continues to deliver to expectations with three new RippleDown licences in Q3 bringing the total to 11 new Tier 1 licences since the partnership renewal in December 2022, an increase of 40% in the current year.

Total Tier 1 licences are 38, currently generating ~$1m per million in recurring revenue.

The company said larger Abbott co-sales (Tier 2) partnership pipeline continues to grow following the first co-sale licence completed with Western Diagnostics Pathology, a Healius (ASX:HLS).

Management expects a second co-sale licence to be signed in Q4 FY23 with further wins to follow into FY24 and importantly noted as the Tier 1 renewals occur, several are expected to convert to higher value Tier 2.

“This partnership with Abbott is starting to mature and feed through some solid contracts,” Wilkie said.

“The company said they expect FY23 to deliver organic revenue growth of around 25% and operating costs to run at about 10% growth so we’ll see some operating leverage roll through.

“Management recently made some long term outlook of delivering annual recurring revenue of $60 million by 2026 so there is a pretty strong growth roadmap there.”

Expand

Originally posted by alnby: ↑

I'm aware that I'm a little obsessed with this segment of the business (it is possibly the real powerhouse of growth though) and I absolutely enjoyed reading about the sharpening focus on it.

"Management expects a second co-sale licence to be signed in Q4 FY23 with further wins to follow into FY24 and importantly noted as the Tier 1 renewals occur, several are expected to convert to higher value Tier 2."

Expand

not disclosing expenditure and rev dollars a bit worrying

I have to admire you guys for holding a stock which CEO Tim Kelsey won't buy on market

BMT Price at posting: 32.0¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

LDX

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

SOL

'Soul Patts' sees profit drop 27.8%, pushed down by Bricksworks' 130% slump

ICL

HotCopper users wait for diamond drills as Iceni flags low grades in aircore drill run at 14 Mile Well

ITM

iTech boosts copper-gold-silver mineralisation at NT's Reynold's Range

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 7 Last

Add BMT (ASX) to my watchlist

(20min delay)
Last 30.5¢		Change -0.005(1.61%)		Mkt cap ! $88.24M

Open	High	Low	Value	Volume
31.5¢	33.0¢	30.5¢	$161.3K	505.5K

Buyers (Bids)

No.	Vol.	Price($)
1	5000	30.0¢

Sellers (Offers)

Price($)	Vol.	No.
31.5¢	27386	2

View Market Depth

No.	Vol.	Price($)
1	5000	0.300
1	15000	0.290
1	1800	0.285
2	153747	0.280
2	4363	0.275

Price($)	Vol.	No.
0.315	27386	2
0.320	120000	2
0.330	65189	3
0.335	81376	2
0.340	30000	1

Last trade - 15.51pm 25/09/2024 (20 minute delay)

BMT (ASX) Chart

Ann: Q3 FY23 Trading Update Presentation, page-7

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

'Soul Patts' sees profit drop 27.8%, pushed down by Bricksworks' 130% slump

HotCopper users wait for diamond drills as Iceni flags low grades in aircore drill run at 14 Mile Well

iTech boosts copper-gold-silver mineralisation at NT's Reynold's Range

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Q3 FY23 Trading Update Presentation, page-7

Top Stories

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

'Soul Patts' sees profit drop 27.8%, pushed down by Bricksworks' 130% slump

HotCopper users wait for diamond drills as Iceni flags low grades in aircore drill run at 14 Mile Well

iTech boosts copper-gold-silver mineralisation at NT's Reynold's Range

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News